Clinical Trial Update: Study Evaluating the Safety and Efficacy of NCX 4251 Ophthalmic Suspension for the Treatment of Blepharitis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the safety and efficacy of NCX 4251 ophthalmic suspension for blepharitis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Blepharitis

Drugs mentioned

• NCX 4251 ophthalmic suspension (NCX 4251)

Snippet

Sponsor: Nicox Ophthalmics, Inc. | Conditions: Blepharitis | Phase 2 | Status: COMPLETED | Results posted: 2022-12-14